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Disseminated Bacille Calmette-Guérin infection at a glance:  
a mini review of the literature
Abstract
Introduction: Immunodeficient children are at a high risk of disseminated Bacillus Calmette-Guérin [BCG] infection. We assessed 
the literature on clinical manifestations of BCGosis in children with specific primary immunodeficiencies. 
Material and methods: We conducted a systematic review of clinical practice articles by searching Medline, PubMed, Embase, 
Scopus, Web of Science and Google Scholar from their inception to date. 
Results: Thirty-seven articles were included regarding BCG vaccination and its dissemination in children with primary immuno-
deficiencies. Articles on dissemination after intravesicular BCG were excluded from the study. 
Conclusions:  Since disseminated BCG vaccination may be the first manifestation of a  primary immunodeficiency disease, 
a comprehensive search for immunological defects in children developing these problems after BCG vaccination seems rational. 
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Introduction
Considering that tuberculosis affects about 
one-third of the world’s population and is the 
leading infectious cause of death in the world, 
immunization with Bacille Calmette-Guérin 
(BCG) is recommended to protect children against 
tuberculosis [1]. BCG immunization with a live 
attenuated bacterial vaccine derived from Myco-
bacterium bovis was first used in 1921 [2, 3] as 
the primary prophylaxis against tuberculosis. It 
is the most widely administered vaccine in the 
world [4]. BCG immunization during the neonatal 
period protects at least until 5 years of age from 
the most severe consequences of tuberculosis (TB) 
[5], such as miliary tuberculosis and tuberculosis 
meningitis [6], and therefore, the World Health 
Organization (WHO) recommends vaccination in 
high burden countries [2]. Although safe, BCG 
vaccination may be associated with several com-
plications, ranging from a regional disease called 
BCGitis to a disseminated disease, namely BCGo-
sis [7, 8]. Adverse reactions are rare (up to 23.8% 
of cases) [9], with the most frequent one — puru-
lent regional lymphadenitis — presenting as local 
swelling and erythema [4], followed by bone in-
fection as the second most frequent complication 
[9]. Vaccination technique, dose and preparation 
of the vaccine and the BCG strain are significant 
risk factors [4, 10].  It has been reported that 
T cell counts in healthy infants may be suppres-
sed after BCG vaccination but these quantitative 
changes have not been associated with functio-
nal derangements [11, 12]. Disseminated BCG 
infection, a  lethal event in 50 to 71% of cases, 
is somewhat rarer with an estimated incidence 
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of 0.1 to 4.3 per one million vaccinated children 
[9, 13]. Immunocompromised patients are not 
only susceptible to mycobacterial diseases, but 
also to the BCG vaccine complications [8]. These 
individuals may experience dissemination of the 
bacilli due to their underlying immunological 
defects. Disseminated BCG infection has been 
reported in severe combined immunodeficiencies 
[SCID], chronic granulomatous disease (CGD), 
complete DiGeorge syndrome and mandelian 
susceptibility to mycobacterial disease (MSMD) 
with underlying genetic defects [9].
The aim of this study is to evaluate the most 
frequent clinical manifestations of disseminated 
BCG infections in vaccinated children with uni-
dentified primary immunodeficiencies at the time 
of neonatal immunization. 
Material and methods
We conducted a systematic review of scienti-
fic medical literature (Medline, PubMed, Embase, 
Scopus, Web of Science and Google Scholar), i.e. 
articles published in English on the clinical ma-
nifestations of disseminated BCG infection, with 
no time limitation — from the inception of the 
databases to date. BCG complications, BCGitis, 
BCGosis, and disseminated BCG infection were 
searched through the literature. We used free texts 
and their related articles to search PubMed, ISI 
Web of Science and EMBASE. More than 50 pu-
blished articles from all over the world, including 
original articles, review articles and case reports 
were used. All the articles on disseminated BCG 
infection following intravesicular BCG were exc-
luded from the study. 
Discussion
The aim of the article is to review the as-
sociated signs of disseminated BCG infection 
in addition to the clinical manifestations of the 
specific underlying immunodeficiency disorder. 
BCG vaccination may be associated with variable 
local and systemic complications. Disseminated 
BCG infection, although rare, is a devastating 
complication of inadvertent BCG immunization 
in immunocompromised children. The most 
common immunodeficiencies connected with the 
dissemination of BCG following immunization 
include SCID, MSMD, CGD, DiGeorge, common 
variable immunodeficiency (CVID), NF-kappa B 
essential modulator (NEMO), tyrosine kinase 2 
(TYK2) and human immunodeficiency virus 
[14] infection. Surprisingly, BCG dissemination 
has also been reported as a rare event in a case 
of CVID [15, 16]. Previous studies comparing 
disseminated BCG infection in SCID and CGD 
reported that many CGD patients are more prone 
to cure with the anti-TB regimen in contrast to 
the SCID patients [8, 17–19]. CGD patients are 
more likely to present with lymphadenitis [8, 
20]. MSMD is a clinical phenotype, extending 
beyond mycobacterial diseases which should 
be considered in all patients presenting with 
nontuberculous mycobacterial infections such 
as Mycobacterium bovis [21]. The subjects who 
develop mycobacterial disease caused by BCG, 
environmental mycobacteria (EM) and M. tuber-
culosis are typically resistant to other infections 
except salmonella [22]. By contrast, patients with 
CGD are less susceptible to EM [22]. The median 
age of onset of BCGosis reported by Ying et al. and 
Al-Hojaj et al. in their studies were 3.6–4 months 
[23, 24]. BCG-induced disease phenotypes were 
designated in 2006 by Hesseling et al. as a local, 
regional, distant or disseminated pattern with the 
two first conditions known as BCGitis and the 
latter two identified as BCGosis [25]. Definitive 
disseminated BCG infection is diagnosed basing 
on the existence of systemic symptoms such as 
fever, malaise, fatigue, weight loss or stunted 
growth and two or more areas of involvement 
beyond the BCG vaccination site, in addition to 
identification of Mycobacterium bovis BCG stra-
in by culture and/or standard polymerase chain 
reaction (PCR), as well as histopathologic chan-
ges with granulomatous inflammation. Areas of 
involvement may include skin papules, nodules, 
or ulcers; lymphadenitis; lung infection; liver or 
spleen enlargement; osteomyelitis; mechanical 
obstructions of the respiratory or gastrointestinal 
tracts; malabsorption of nutrients and diarrhea 
[21]. Finding similar clinical manifestations 
as mentioned above through identification of 
Mycobacterium tuberculosis complex by PCR, 
without differentiation of Mycobacterium bovis 
BCG substrain or other members of the Myco-
bacterium tuberculosis complex and negative 
mycobacterial cultures, with the presence of 
typical histopathologic changes with granulo-
matous inflammation is indicative of probable 
disseminated BCG infection [13]. Historically, this 
is a disease of infants and young children [26]. 
Casanova in 1995 reviewed 121 published case 
reports of disseminated BCG infections and found 
61 cases of definitive immunodeficiency among 
them [27]. Initial presentation includes usually 
local erythema preceding  progressively enlar-
ging swelling at axillary region ipsilateral to the 
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injection site, accompanying pus discharge. In-
termittent fever, generalized lymphadenopathies, 
hepatosplenomegaly, cough, bone involvement, 
weight loss and skin rash may develop later in the 
course of the disease [15, 26]. Refractory cough 
due to recurrent lower respiratory infections is 
another presentation of the disease reported in 
several cases [28], without significant changes 
in chest radiography [4]. Osseous involvement 
is another finding in disseminated BCG infection 
[6]. Hemophagocytic lymphocytic histiocytosis 
(HLH) is a rare complication of the disease [29].
Lymphadenopathies are the most common 
presenting features of the disease involving axil-
lary, cervical, mediastinal, retroperitoneal, me-
senteric and inguinal regions usually with a slow 
resolution after treatment [4]. In contrast to tu-
berculosis, which may present with inflammatory 
conglomerations of bowel loops with adherent 
omentum and adjacent lymphadenopathy, this 
finding is not a common feature in children with 
disseminated BCG infection [30].
Pulmonary involvement is usually associated 
with pulmonary symptoms, including chronic 
cough with intermittent fever. Plain radiography 
or CT scan of the chest may reveal pneumonic 
infiltration [22] and hilar/mediastinal lymphade-
nopathies. Pulmonary nodularity may occur due 
to the disseminated BCG disease. 
Skeletal involvement may affect the hands, 
arms, legs, vertebrae and orbit. BCG osteomyelitis 
usually occurs in the epiphysis and metaphysis 
and can cross the growth plate with soft tissue 
swelling around the affected bone [31].
Hepatic and splenic lesions with variable 
sizes most commonly presenting as numerous 
small nodules detected by imaging modalities, 
including ultrasound evaluation or CT scan have 
been reported in patients with disseminated BCG 
infection [4].
Disseminated BCG infection is extremely dif-
ficult to treat as there is a low chance of complete 
eradication of the microorganism [32].
A key point in treating disseminated BCG 
infections is to identify the culprit organism as 
soon as possible to start appropriate antibiotics 
[33]. However, in the patients with compatible 
clinical signs and symptoms, suspected of pri-
mary immunodeficiencies, a positive acid-fast 
bacilli smear is sufficient for anti-TB treatment 
to be initiated promptly, with no delay to obtain 
the PCR results or cultures [34].
While there are no clear guidelines on the 
best mode of treatment for disseminated BCG in-
fection, aggressive therapy involving at least four 
anti-TB drugs [including isoniazid, rifampicin 
and ethambutol plus an additional agent such as 
quinolone, aminoglycoside and clarithromycin] 
are usually initiated until complete recovery [32, 
35, 36]. Then, the treatment is continued with 
a two-drug prophylactic regimen. Prolonged use 
of these drugs may cause organ toxicities and 
drug resistance [32], which necessitates treatment 
modification [36]. Because of the BCG resistance 
to pyrazinamide, there is no place for this drug in 
the treatment protocol of these children [37]. Low- 
-level isoniazid resistance to Connaught strains 
has been reported in Denmark [36]. During the 
treatment period, close follow-up and observa-
tion of the patients is essential for reviewing the 
regimen when the culture and sensitivity results 
become available [36]. 
IFN-g is an effective modality of treatment 
in addition to anti-TB drugs in treating patients 
with MSMD and CGD [11]. 
Whenever possible and available, hema-
topoietic stem cell transplantation (HSCT) is 
another treatment option for these children [37]. 
However, post-transplant inflammatory compli-
cations  developed upon immune reconstitution 
may necessitate immune suppression which not 
only may affect immune recovery but also may 
increase the risk of opportunistic infections [32].
Unfortunately, disseminated BCG disease 
is one of the most common causes of death in 
patients with primary immunodeficiency dise-
ases due to clinical and conventional diagnostic 
delay [34].
Conclusions
A history of parental consanguinity and se-
rious recurrent infections or death in other family 
members are two important risk factors that sho-
uld be considered before BCG vaccination. Practi-
cally, family history awareness of vaccine-related 
complications should be promoted in antenatal 
visits to induce further detailed evaluations and 
counseling in a sufficient period of time. Since 
disseminated BCG vaccination may be the first 
manifestation of a primary immunodeficiency 
disease which may lead to death later in the life, 
a comprehensive search for immunological de-
fects in children developing these problems after 
BCG vaccination seems rational. 
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